GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Azitra Inc (AMEX:AZTR) » Definitions » Asset Turnover

AZTR (Azitra) Asset Turnover : 0.00 (As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Azitra Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Azitra's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Azitra's Total Assets for the quarter that ended in Sep. 2024 was $6.83 Mil. Therefore, Azitra's Asset Turnover for the quarter that ended in Sep. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Azitra's annualized ROE % for the quarter that ended in Sep. 2024 was -82.50%. It is also linked to ROA % through Du Pont Formula. Azitra's annualized ROA % for the quarter that ended in Sep. 2024 was -59.09%.


Azitra Asset Turnover Historical Data

The historical data trend for Azitra's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Azitra Asset Turnover Chart

Azitra Annual Data
Trend Dec21 Dec22 Dec23
Asset Turnover
0.01 0.03 0.11

Azitra Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.11 - - -

Competitive Comparison of Azitra's Asset Turnover

For the Biotechnology subindustry, Azitra's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Azitra's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Azitra's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Azitra's Asset Turnover falls into.



Azitra Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Azitra's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0.686/( (7.167+5.115)/ 2 )
=0.686/6.141
=0.11

Azitra's Asset Turnover for the quarter that ended in Sep. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=0/( (3.883+9.777)/ 2 )
=0/6.83
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Azitra  (AMEX:AZTR) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Azitra's annulized ROE % for the quarter that ended in Sep. 2024 is

ROE %**(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=-4.036/4.892
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-4.036 / 0)*(0 / 6.83)*(6.83/ 4.892)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.3962
=ROA %*Equity Multiplier
=-59.09 %*1.3962
=-82.50 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Azitra's annulized ROA % for the quarter that ended in Sep. 2024 is

ROA %(Q: Sep. 2024 )
=Net Income/Total Assets
=-4.036/6.83
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-4.036 / 0)*(0 / 6.83)
=Net Margin %*Asset Turnover
= %*0
=-59.09 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Azitra Asset Turnover Related Terms

Thank you for viewing the detailed overview of Azitra's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Azitra Business Description

Traded in Other Exchanges
N/A
Address
21 Business Park Drive, Branford, CT, USA, 06405
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin. The company has built a proprietary platform that includes a microbial library comprised of bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen the library of strains for drug-like molecules. The platform also utilizes a licensed genetic engineering technology, which can enable the transformation of previously genetically intractable strains.
Executives
Norm Staskey officer: Chief Financial Officer 21 BUSINESS PARK DRIVE, BRANFORD CT 06405
Francisco D. Salva director, officer: President and CEO 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Travis Whitfill director, officer: Chief Operating Officer C/O IN8BIO,INC., 79 MADISON AVENUE, NEW YORK NY 10016
Fletcher Aaron G.l. 10 percent owner 40 GUEST STREET, BOSTON MA 02135
Leslie W. Kreis 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Andrew Mcclary director 21 BUSINESS PARK DRIVE, BRANFORD CT 06405
Aktiengesellschaft Bayer 10 percent owner BAYERWERK, GEBAEUDE W11, KAISER-WILHELM-ALLEE, LEVERKUSEN 2M D-51368
Bios Azitra Co-invest I, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bayer Us Holding Lp 10 percent owner 100 BAYER BOULEVARD, WHIPPANY NJ 07981
Bayer Healthcare Llc 10 percent owner
Bios Equity Partners Iii, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii Qp, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii Nt, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Capital Management, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107